Tag: DEA

3/2/21--The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. Read

3/2/21--DEA Acting Administrator D. Christopher Evans today announced the release of the 2020 National Drug Threat Assessment, DEA’s annual publication outlining the threats posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. Read

8/21/20--On Tuesday, the Ninth Circuit filed a one-page order denying the United States Drug Enforcement Administration (DEA)’s motion to dismiss in a lawsuit in which the Scottsdale Research Institute and its president, Dr. Suzanne Sisley, are attempting to reschedule medical marijuana. Read

5/28/20--Researchers and veterans are challenging the DEA's denial of prior cannabis rescheduling requests. The Scottsdale Research Institute (SRI) filed suit last week in the U.S. Ninth Circuit Court of Appeals, asking for a review of DEA’s scheduling determinations in 2020, 2016 and 1992. In all cases, the agency denied the petitions, citing statutory obligations to maintain the status of cannabis as a Schedule I drug under the Controlled Substances Act. Read

3/20/20--In 2016, the US Drug Enforcement Administration said it would, for the first time, open applications for those hoping to become federally-licensed cannabis researchers. The details came four years later. The DEA announced Friday, to “expand opportunities for marijuana growers who seek to grow marijuana for research purposes and outline the agency’s proposed process for administering the new program, consistent with applicable law.” There will then be a public comment period. Read